INT283201

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.00
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 0.56
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (Gnas) GTPase activity (Gnas) cytoplasm (Gnas)
signal transducer activity (Gnas) cytosol (Gnas) signal transduction (Gnas)
Anatomy Link Frequency
immune system 1
Gm4658 (Mus musculus)
Gnas (Mus musculus)
Pain Link Frequency Relevance Heat
beta blocker 1 5.00 Very Low Very Low Very Low
agonist 1 5.00 Very Low Very Low Very Low
fibrosis 1 5.00 Very Low Very Low Very Low
depression 1 5.00 Very Low Very Low Very Low
Inflammation 1 5.00 Very Low Very Low Very Low
Pain 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pressure Volume 2 Under Development 1 97.84 Very High Very High Very High
Anaphylaxis 1 97.58 Very High Very High Very High
Muscular Dystrophy 43 90.16 High High
Duchenne Muscular Dystrophy 4 16.04 Low Low
Respiratory Failure 2 5.00 Very Low Very Low Very Low
Depression 2 5.00 Very Low Very Low Very Low
Stress 2 5.00 Very Low Very Low Very Low
Fibrosis 1 5.00 Very Low Very Low Very Low
Toxicity 1 5.00 Very Low Very Low Very Low
Coronary Heart Disease 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Phosphorodiamidate morpholino oligomers (PMOs; figure 1) are non-toxic, and in the mdx mouse model of DMD they were the most effective oligomer chemistry for inducing exon skipping and restoring long-lasting (weeks) dystrophin expression after intravenous or intramuscular injection.21–24 PMOs, unlike other antisense oligonucleotides, are uncharged, not metabolised, and in preclinical or clinical studies were not associated with activation of the immune system, anaphylaxis, hypotension, or anti-arrhythmias.25 On the basis of these data, we have studied the safety and biochemical efficacy of AVI-4658, a PMO designed to target exon 51 that is delivered by intramuscular injection.
AVI-4658 Regulation (target) of exon in immune system associated with pressure volume 2 under development, anaphylaxis and muscular dystrophy
1) Confidence 0.00 Published 2009 Journal Lancet Neurol Section Body Doc Link PMC2755039 Disease Relevance 0.56 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox